M yocardial infarction is one of the leading killers in the Western world today, and ever increasing obesity rates in the industrialized world make cardiovascular disease a growing threat to public health. 1 Myocardial infarction is characterized by a blockage of the coronary circulation, usually caused by atherosclerotic plaque rupture, leading to cessation of oxygen and nutrient delivery to the myocardium. Timely restoration of flow to the affected area, reperfusion, is paramount. However, this treatment method is also a doubleedged sword; although necessary to salvage cardiac function, it also evokes reperfusion damage, a combination of oxidative stress and inflammation that results in additional myocardial injury. 2 Leukotrienes are potent proinflammatory lipid mediators synthesized from arachidonic acid via the actions of 5-lipoxygenase and 5-lipoxygenase-activating protein.
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CysLT 2 R, in humans, is expressed in umbilical vein endothelial cells, macrophages, 5,6 platelets, 7 the cardiac Purkinje system, 8 and coronary endothelial cells. 9 CysLT 2 R research had been previously hampered by a lack of selective pharmacological agents, 10 the majority of work instead using the nonselective cysLT antagonist/partial agonist Bay-u9773 11 or genetic models of CysLT 2 R expression modulation. 11, 12 However, recent studies have characterized 2 novel CysLT 2 R-selective antagonists: HAMI3379 13 and BayCysLT 2 , [14] [15] [16] which are proving to be useful as tools in eicosanoid research.
There is evidence linking cysLTs to cardiovascular disease and inflammation. Expression of components of the leukotriene synthesis pathway is found in human atherosclerotic lesions. 17 Furthermore, genetic polymorphisms in 5-lipoxygenase pathway genes have been correlated to increased myocardial infarction and stroke risk in some populations 18 but not all. 19, 20 CysLT 2 R can mediate vascular permeability, 12, 21 susceptibility to gastrointestinal tract inflammation, 22 and increased vulnerability to ischemic injury in the heart 11 and brain. 16, 23 CysLT 2 R expression is increased after hypoxic/ ischemic stress. 11, [23] [24] [25] Previous work from our laboratory has shown that CysLT 2 R-selective antagonism can abrogate myocardial ischemia/reperfusion injury in transgenic mice overexpressing the human CysLT 2 R receptor in vascular endothelium (hEC-CysLT 2 R). However, we were unable to delineate the relative roles of the transgenic endothelial CysLT 2 R versus endogenous murine CysLT 2 R present on various cell types.
To study this, we have created a novel mouse model by crossing CysLT 2 R-knockout mice (KO) with hEC-CysLT 2 R mice (EC), resulting in a model with selective endothelial CysLT 2 R expression. Using these novel mice, we examine how CysLT 2 R mediates postischemic myocardial injury and vascular inflammatory responses.
Materials and Methods
A summary of the murine genotypes used in this study can be found in the Table. Detailed Materials and Methods are available in the online-only Supplement.
Results

Transgenic CysLT 2 R Is Found in Both Tissues and Circulating Cells
Tie2 is known to be expressed in certain circulating leukocytes in addition to endothelial cells and, thus, we compared transgenic CYSLTR2 mRNA expression levels in tissues and circulating cells from mice possessing the CYSLTR2 transgene. Comparable amounts of CYSLTR2 expression was noted between EC and EC/KO mice in lung tissues. Less CYSLTR2 expression was found in peripheral blood leukocytes and bone marrow cells in both EC and EC/KO mice relative to lung expression. We also confirmed the absence of transgene expression in WT mice, as well as the absence of endogenous murine Cysltr2 expression in EC/KO mice ( Figure I in the online-only Data Supplement). These results indicate that Tie2-expressing nonendothelial cells do not comprise the bulk of transgenic CYSLTR2 present in our overexpression mouse models. In addition, there is no difference in transgenic CYSLTR2 expression between EC and EC/KO mice. This indicates that any phenotypic differences noted between EC and EC/KO mice are likely the result of removal of the endogenous murine CysLT 2 R.
Endothelium-Targeted CysLT 2 R Overexpression Does Not Exacerbate Infarction Damage in the Absence of Endogenous CysLT 2 R
Our previous findings have established that transgenic CysLT 2 R overexpression in the endothelium, in the presence of endogenous murine CysLT 2 R expression, results in significantly increased infarction volume after myocardial ischemia/ reperfusion in mice. 11, 14 However, transgenic mice without endogenous CysLT 2 R expression (EC/KO) did not show this phenomenon ( Figure 1 ). Indeed, both WT (23.2±2.2%, n=13) and EC/KO (24.0±3.0%, n=14) groups showed significantly lower infarction volumes than EC mice (47.2±1.9%, n=12; P<0.001 against both groups). Volume at risk did not vary between any of the experimental groups ( Figure 1B ). We also found that CysLT 2 R-knockout mice (KO; 17.8±2.2%, n=12) had a tendency of lower infarction volumes than WT and EC/ KO groups ( Figure 1C ; P=0.096 versus WT, P=0.11 versus EC/KO). These findings were unexpected because endogenous CysLT 2 R expression is significantly less than transgene expression. 21 These results indicate that CysLT 2 R-mediated exacerbation of myocardial ischemia/reperfusion injury is not solely mediated by endothelium-targeted CysLT 2 R.
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Vascular Permeability Responses in EC/ KO Mice Differ From Those in EC Mice
Given that CysLT 2 R-mediated myocardial injury seems not to be exclusively mediated by the endothelium-overexpressed CysLT 2 R transgene, we sought to investigate how and to what extent knockout of endogenous CysLT 2 R would affect endothelial/vascular permeability. This is especially pertinent because based on previous work 11, 14 CysLT 2 R-mediated endothelial permeability facilitates tissue injury by permitting leukocyte extravasation, inflammation, and edema. We examined FITC-albumin extravasation from postcapillary venules in the cremaster muscle both before and after exogenous leukotriene stimulation. Minimal extravascular fluorescence accumulation before leukotriene stimulation was observed in WT, KO, and EC/KO mice. However, EC mice showed significantly higher absolute fluorescence accumulation ( Figure 2B ), and rate of fluorescence accumulation ( Figure 2C ) as previously determined, which we surmised, was because of surgery-induced cysLT release from resident tissue macrophages/mast cells activating high numbers of endothelial cell-expressed CysLT 2 Rs. 12 Administration of cysLTs resulted in an increase in absolute FITC-albumin extravasation in all experimental groups ( Figure 3A ). EC and EC/KO groups demonstrated increased total leakage and rate of leakage versus the WT group post-cysLTs. However, cysLT-challenged KO mice showed significantly less FITC-albumin extravasation compared with WT mice ( Figure 3B and 3C). Interestingly, EC/KO mice, despite possessing identical transgenic overexpression of CysLT 2 R in the endothelium as EC mice, only showed elevated extravascular FITC-albumin accumulation versus WT mice after cysLT stimulation. This is in contrast to the increased FITCalbumin extravasation observed in EC mice compared with WT mice, both before and after cysLT stimulation.
Genetic Knockout of Endogenous CysLT 2 R Reduces Basal Rolling Leukocyte Flux in Cremaster Vasculature
The endothelium plays a large role in regulating leukocyte capture and transmigration during inflammatory responses, 26 and we have previously reported increased leukocyte adhesion molecule mRNA expression in EC mice after ischemia/reperfusion injury. 11, 14 To examine whether CysLT 2 R expression modulation affects leukocyte recruitment and behavior, we examined leukocyte flux under basal and cysLT-stimulated conditions in the cremaster vasculature. Rolling leukocyte flux (the number of rolling leukocytes passing through the vasculature/min) was higher in mice expressing endogenous CysLT 2 R (WT: 38±6 cells/min, n=12; EC: 35±6, n=16) than mice lacking endogenous receptor (KO: 20±3, n=16; EC/KO: 24±3, n=14) and mice under basal conditions ( Figure 4 ). Mice that possessed transgenic endothelium-targeted CysLT 2 R overexpression (EC and EC/KO) did not show significantly altered basal rolling leukocyte counts versus nontransgenic counterparts (WT and KO). Complete blood counts for all genotypes were undertaken, and no significant differences in baseline leukocyte numbers or differential counts were detected (data not shown).
Endothelial-Targeted CysLT 2 R Overexpression Results in Diminishing Leukocyte Flux in Cremaster Vasculature After Leukotriene Stimulation
Next, we investigated the effects of cysLT stimulation on rolling leukocyte flux in murine cremaster postcapillary venules. WT mice (n=6) showed an increase in rolling leukocyte flux after 5 minutes postcysLT stimulation (+13±5 cells/min; P=0.07 versus start), and this was maintained until the end of the experiment at 15 minutes (+12±5; P=0.07 versus start). CysLT-stimulated cremaster preparations of KO mice (n=6) did not show significant changes in rolling leukocytes throughout the duration of the experiment. However, cysLT stimulation of the cremaster vasculature in mice possessing transgenic endothelial CysLT 2 R overexpression resulted in a decrease in rolling leukocytes. Rolling leukocyte count per minute dropped in EC mice (n=9) by 5 minutes (−8±5) and had significantly decreased by the 15-minute time point (−13±6; P=0.04 versus start). Rolling leukocyte flux in EC/KO mice (n=7) was not changed at 5 minutes (−2±2) but showed a significant decline by 15 minutes (−10±3; P=0.002 versus start). Changes in rolling leukocyte flux in EC and EC/KO mice were statistically 
Cysteinyl Leukotriene Stimulation Results in Increased Leukocyte Slow-Rolling Fraction in Cremaster Vasculature in Mice Expressing Endothelial CysLT 2 R
Before firm adhesion and transmigration, leukocytes undergo slow rolling, a phenomenon characterized by leukocyte velocity decreasing to <10 μm/s. Slow rolling is mediated by E-selectin/CD18 binding and is triggered by proinflammatory cytokines. 27, 28 We examined rolling leukocyte velocity in cremaster venules in the absence and presence of cysteinyl leukotriene stimulation. Rolling leukocyte velocity distribution in the unstimulated cremaster muscle did not differ significantly among the 4 genotypes. However, WT (n=6 mice, 58% slow rolling leukocytes → 79%), EC (n=8 mice, 65% → 78%), and EC/KO (n=7 mice, 59% → 70%) groups all presented a significant shift in rolling leukocyte velocity distribution toward increased slow-rolling (sub 10 μm/s) at 5 minutes postcysLT stimulation ( Figure 6 ). KO mice (n=6 mice, 61 → 64%) did not display this trend. The presence of this phenomenon in EC/KO mice indicates that it is the endothelial CysLT 2 R niche that drives promotion of slow-rolling leukocytes. Interestingly, although WT mice showed a significantly increased proportion of slow-rolling leukocytes through all 3 poststimulation time points, both EC and EC/KO mice saw slow-rolling cell fraction return to prestimulation levels by 10 minutes.
Median rolling leukocyte velocity in the unstimulated cremaster muscle did not differ significantly between the 4 genotypes. However, median rolling leukocyte velocity in WT, EC, and EC/KO mice all decreased significantly at 5 minutes postleukotriene stimulation. This phenomenon persisted in WT and EC mice at 10 and 15 minutes (albeit nonsignificantly in the latter group) but was transient in EC/KO mice. In addition, median velocity in EC mice was significantly lower than EC/KO mice at 10 minutes postcysLT stimulation, and both WT and EC mice showed significantly lower median velocity compared with EC/KO mice at 15 minutes poststimulation ( Figure 7 ). This indicates that nonendothelial CysLT 2 R activation may also play a role in mediating/sustaining leukocyte slow-rolling.
Discussion
Endothelial CysLT 2 R Is Not the Sole Mediator of CysLT 2 R-Mediated Ischemia/ Reperfusion Injury Exacerbation
Endothelial expression of functionally relevant CysLT 2 Rs has been well established for almost a decade now, 17, 21 and endothelial-targeted overexpression of CysLT 2 R results in exacerbation of vascular permeability, 12,21 edema, 11 upregulation of cell adhesion molecules, 11, 14 and myocardial infarction damage. 11, 14 The ability of CysLT 2 R pharmacological antagonism to abolish these phenomena 12, 14 lent support to the idea that endothelial-expressed CysLT 2 R was the principal mediator of these effects. Given the disparity in levels between endogenous murine CysLT 2 R expression and the overexpressed endothelial-targeted hCysLT 2 R transgene, 21 it was also logical to think that these biological responses were endothelium driven.
However, our experiments using a novel endotheliumlimited CysLT 2 R-overexpressing mouse model indicate that CysLT 2 R-mediated exacerbation of inflammation is only partially driven by endothelial cell-expressed receptors, and that other CysLT 2 R receptor niches may play a vital role in initiating and mediating the inflammatory response. Despite possessing the same overexpression of endothelial hCysLT 2 R as the EC model, EC/KO mice have significantly less severe myocardial damage after ischemia/reperfusion. Because transgenic CysLT 2 Rs account for the majority of endothelial CysLT 2 R in EC mice, 21 it was not expected that removal of the murine endothelial receptor would affect CysLT 2 R-mediated mechanisms involving the endothelium, indicating that the endothelium is not the sole mediator of increased I/R injury in EC mice. We also note for the first time that KO mice show a tendency for reduced I/R damage versus WT counterparts. The reason that the difference between damage in KO and WT mice is relatively small compared with that between WT and EC mice is that basal CysLT 2 R expression in murine cardiac vasculature is low. 9 However, basal human CysLT 2 R expression is higher, 8 and leukotriene production and leukotriene receptor expression are elevated in pathological states, 11, 29, 30 indicating that our EC model more closely represents human CysLT 2 R expression levels. Indeed, our experimental data ( Figure II in the onlineonly Data Supplement) indicate that human CYSLTR2 expression is higher than that found in our EC mice.
Explaining our results required closer examination of the various proinflammatory mechanisms stemming from CysLT 2 R activation. We have shown that basal rolling leukocyte flux is significantly higher in mice that possess endogenous nonendothelial CysLT 2 R (WT and EC groups) compared with mice that do not (KO and EC/KO groups), regardless of presence or absence of transgenic endothelial CysLT 2 R. Although leukocyte recruitment to injured tissue is a key component of tissue repair, 31, 32 exacerbated leukocyte recruitment and improper resolution of the inflammatory response can result in additional injury. 31 We have previously shown that transgenic overexpression of endothelial CysLT 2 R results in vascular hyperpermeability, 12 and our EC/KO model was in agreement with this finding, showing significantly elevated extravascular FITC-albumin accumulation after cysLT stimulation. The extent and magnitude of the vascular permeability response in EC/KO mice was comparable with that seen in EC mice, indicating that nonendothelial CysLT 2 R does not play a significant role in CysLT 2 R-mediated vascular hyperpermeability.
The presence of rolling leukocytes does not automatically translate into leukocyte transmigration. Indeed, the presence of a patrolling vascular leukocyte reservoir consisting primarily of rolling or crawling monocytes that do not extravasate until after exposure to irritants and injury has been characterized in the mesenteric and coronary vasculature. 32, 33 However, we saw a significant decrease in rolling leukocyte flux as well as a transient but significant increase in slow-rolling leukocyte proportion in EC and EC/KO mice after cysLT stimulation. These findings, in combination with the aforementioned cysLT-induced hyperpermeability response in EC and EC/ KO mice, support a mechanism whereby CysLT 2 R activation results in increased rolling leukocyte flux, decreased rolling leukocyte velocity, and vascular hyperpermeability, resulting in the elevated edema and leukocyte extravasation into the injured myocardium, which have been shown to be hallmarks of CysLT 2 R-mediated exacerbation of I/R injury. 11, 14 However, although vessels in EC mice showed leakage in the absence of exogenous cysLT stimulation, vessels in EC/ KO mice did not. Moos et al 12 attributed the phenomenon in EC mice to small amounts of leukotrienes liberated during the surgical exposure of the cremaster muscle taking advantage of an increased abundance of endothelial CysLT 2 R. If this is the case, why do these liberated leukotrienes not exert a similar effect on vessels in EC/KO mice? The answer may be that leukotrienes released during tissue injury do not directly activate endothelial CysLT 2 R. Rather, trauma results in localized leukotriene production/release 29, 34 and the subsequent activation of nonendothelial CysLT 2 Rs. This in turn results in cysLT production in close proximity to endothelial cells, a vital feature given the short half-lives of LTC 4 and LTD 4 , resulting in the activation of endothelial CysLT 2 R and autocrine cysLT production mechanisms. Sufficient leukotriene presence (ie, exogenous application) would be able to bypass the nonendothelial step and directly activate endothelial receptors, explaining how EC/KO mice can still present hyperpermeability after exogenous stimulation. The exact cellular identity of the nonendothelial CysLT 2 R niches being activated in mice has yet to be determined; however, leukocytes and other circulatory cells are leading candidates because CysLT 2 R is expressed by monocytes, macrophages, eosinophils, 8 and platelets 7 in humans. Eosinophils, 15 mast cells, macrophages, 35 and parenchymal cells 36 are capable of producing cysLTs, and neutrophils and monocytes produce the cysLT precursor leukotriene A 4 , 37, 38 which is converted to LTC 4 by endothelial cells and platelets. 38 Finally, endothelial cells produce LTC 4 in an autocrine manner on CysLT 2 R activation. 15 A limitation of the study is using the cremaster vasculature to extrapolate findings to the coronary circulation, given the known physiological and anatomic heterogeneity among microvascular beds. 39 However, the observations in the cremaster vasculature do not contradict the post-I/R injury damage phenotypes detected in the myocardium. A novel and nonobtrusive method of real-time cardiac intravital microscopy imaging has just been realized, 32 affording an opportunity to examine the similarities and differences in response to cysLT stimulation directly when this technique becomes more widely available. Furthermore, although the Tie2 promoter, used in our transgenic mice, specifies endothelial-targeted gene expression, it may also lead to expression in a small subset of monocytes, termed Tie2-expressing monocytes Figure 6 . Rolling leukocyte velocity distributions in mice before and after cysteinyl leukotriene (cysLT) stimulation. Histograms of rolling leukocyte velocities in murine cremaster vasculature before and after application of 5 μmol/L cysLTs. Velocities of individual leukocytes from 6 to 9 mice (roughly equal numbers of leukocytes were tracked in each mouse) were calculated, and the results were compiled (n values indicate total number of cells tracked). WT (A-D) mice showed persistent and significant increase in slow-rolling (≤10 μm/s) leukocyte fraction after cysLT application. EC (E-H) and EC/KO (M-P) mice showed a significant increase in slow-rolling leukocyte fraction at 5 minutes that disappeared by the 10-minute mark. KO (I-L) mice did not show any significant change in leukocyte rolling velocity distribution. **P<0.01; ***P<0.001 vs untreated.
(TEMs). 40 These monocytes are highly angiogenic, vital to tumor neovascularization, and are mobilized after ischemia for the revascularization of ischemic tissue. 41 Indeed, the majority of Tie2 + monocytes in mice are resident cluster of differentiation (CD)11b + Gr-1 low/neg monocytes, 42 thought to be instrumental to inflammatory response resolution, 43 therefore, it will be interesting to investigate the role of CysLT 2 R activation/overexpression in this cell population in future studies. We certainly cannot rule out the possibility that the activation of CysLT 2 R on Tie2 + myeloid cells is involved in the mechanisms explored herein. However, our data indicate that these cells do not play a significant role because overexpression of CysLT 2 R on Tie2 + myeloid cells is common to both EC and EC/KO mice, and thus would not explain the differences presented between the 2 genotypes.
Various Tissue-Specific CysLT 2 R Niches Play Divergent yet Synergistic Roles in Mediating CysLT 2 R-Mediated Ischemia/ Reperfusion Injury Exacerbation
We previously proposed a mechanism whereby CysLT 2 R activation after ischemia/reperfusion injury resulted in elevated leukocyte extravasation and increased inflammation, resulting in increased tissue injury. 14 Our present findings indicate that leukotriene release after injury/ischemia activates CysLT 2 R niches, likely circulating leukocytes, and that this facilitates leukocyte recruitment to the site of injury and activation of endothelial CysLT 2 R (possibly via localized cysLT production). Endothelial CysLT 2 R activation results in vascular hyperpermeability, resulting in edema, and an increase in the proportion of slow-rolling leukocytes, promoting Although this phenomenon persisted for the duration of the experiment in WT mice (A), EC mice showed nonsignificantly decreased median velocity relative to 0 minutes at 10 and 15 minutes (B). EC/KO mice showed a return to prestimulation leukocyte median velocity at 10 and 15 minutes poststimulation (D). No change in median velocity was noticed in KO mice (C). In addition, significant differences in median velocity were noted between genotypes as well. **P<0.01; ***P<0.001 vs 0 minutes, #P<0.05; ##P<0.01 vs EC group, †P<0.05; † †P<0.01 vs WT group. leukocyte extravasation. Activation of both endothelial and nonendothelial CysLT 2 Rs likely yields a synergistic effect. Insufficient endothelial CysLT 2 R activation would result in higher numbers of rolling leukocytes that do not extravasate en masse (seen in WT mice), whereas absence of nonendothelial activation would result in limited-rolling leukocyte flux (seen in EC/KO mice), and thus decreased leukocyte migration to the surrounding tissue, regardless of vascular hyperpermeability (Figure 8 ).
In conclusion, we have used a novel endothelium-limited CysLT 2 R-overexpressing mouse model to delineate the differing roles that endothelial and nonendothelial CysLT 2 R niches play in mediating postinjury inflammatory responses. We show that nonendothelial CysLT 2 R niches are vital to leukocyte recruitment and endothelial CysLT 2 R activation, whereas endothelial CysLT 2 R activation mediates extent of vascular permeability. Although further work is required to clarify the precise molecular mechanisms underlying these phenotypes (ie, cytokine release profile or induction of angiogenesis), as well as any involvement by other cell types (ie, adipose tissue) 44 in close proximity to the vasculature, the revelation that endothelial CysLT 2 R activation alone does not govern CysLT 2 R-mediated proinflammatory responses indicates that more attention should be devoted to the role of nonendothelial CysLT 2 R expression in cardiovascular injury. Proposed schematic for human cysteinyl leukotriene receptor 2 (CysLT 2 R) inflammatory response modulation. Injury or proinflammatory stimuli results in the synthesis and release of leukotrienes, which in turn activate CysLT 2 Rs present on resident and circulating cells, most likely leukocytes such as monocytes, macrophages, mast cells, and neutrophils. Activation of these CysLT 2 Rs results in increased leukocyte rolling flux and promotes localized cysLT production, likely via supplying LTA 4 to endothelial cells and platelets. This results in activation of endothelial CysLT 2 Rs, causing increased slow-rolling leukocyte fractions and vascular hyperpermeability, the latter contributing to edema in the affected tissue. These factors, in combination with the aforementioned increased leukocyte rolling flux, promote leukocyte transmigration into the surrounding tissue, resulting in exacerbation of the inflammatory response and elevated tissue damage.
